TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06040541: Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors

Sponsor: Revolution Medicines, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 604 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06040541 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06040541 Rescue Dossier →